Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Search Results (2,051)

Search Parameters:
Keywords = oncological risk

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
19 pages, 1175 KB  
Article
The Effect of the Clinical-Pathological CPS+EG Staging System on Survival Outcomes in Patients with HER2-Positive Breast Cancer Receiving Neoadjuvant Treatment: A Retrospective Study
by Seval Orman, Miray Aydoğan, Oğuzcan Kınıkoğlu, Sedat Yıldırım, Nisanur Sarıyar Busery, Hacer Şahika Yıldız, Ezgi Türkoğlu, Tuğba Kaya, Deniz Işık, Seval Ay Ersoy, Hatice Odabaş and Nedim Turan
Medicina 2025, 61(10), 1813; https://doi.org/10.3390/medicina61101813 (registering DOI) - 9 Oct 2025
Abstract
Background and Objectives: To evaluate the prognostic value of the Clinical–Pathologic Stage–Estrogen receptor status and Grade (CPS+EG) staging system, which combines clinical staging, pathological staging, oestrogen receptor (ER) status, and tumour grade in predicting survival outcomes in patients with human epidermal growth [...] Read more.
Background and Objectives: To evaluate the prognostic value of the Clinical–Pathologic Stage–Estrogen receptor status and Grade (CPS+EG) staging system, which combines clinical staging, pathological staging, oestrogen receptor (ER) status, and tumour grade in predicting survival outcomes in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer receiving neoadjuvant therapy (NACT). Materials and Methods: A retrospective review was performed on 245 female breast cancer patients who received anti-HER2 therapy alongside NACT at the Medical Oncology Department of Kartal Dr Lütfi Kırdar City Hospital, University of Health Sciences, from April 2012 to June 2024. The CPS+EG score was calculated using the MD Anderson Cancer Centre neoadjuvant treatment response calculator. Patients were categorised into two groups based on their CPS+EG score < 3 and ≥3. The primary outcomes assessed were disease-free survival (DFS) and overall survival (OS). Kaplan–Meier and log-rank tests were utilised for time-to-event analysis; Cox regression was used for multivariate analysis. A significance level of ≤0.05 was considered. Results: The median age of the patient cohort was 51 years (range: 27–82 years). Among these patients, 183 (74.6%) had a CPS+EG score less than 3, while 62 (25.3%) exhibited a score of 3 or higher. The median follow-up duration was 37.6 months. The pathological complete response (pCR) rate across the entire cohort was 51.8%. Specifically, the pCR rate was 56.3% in the group with CPS+EG scores below 3, and 38.7% in those with scores of 3 or higher (p = 0.017). Patients with CPS+EG scores less than 3 demonstrated superior overall survival (OS), which reached statistical significance in univariate analysis. Multivariate analysis identified the CPS+EG score as an independent prognostic factor for both overall survival and disease-free survival (DFS), with hazard ratios of 0.048 (95% CI: 0.004–0.577, p = 0.017) and 0.35 (95% CI: 0.14–0.86, p = 0.023), respectively. Conclusions: The CPS+EG score is an independent and practical prognostic marker, particularly for overall survival, in patients with HER2-positive breast cancer who have received neoadjuvant therapy. Patients with a CPS+EG score < 3 have higher pCR rates and survival rates. When used in conjunction with pCR, it can improve risk categorisation and contribute to the individualisation of adjuvant strategies in the post-neoadjuvant period. Due to its ease of calculation and lack of additional costs, this score can be instrumental in clinical practice for identifying high-risk patients. Our findings support the integration of the CPS+EG score into routine clinical decision-making processes, although prospective validation studies are necessary. Full article
(This article belongs to the Special Issue New Developments in Diagnosis and Management of Breast Cancer)
Show Figures

Figure 1

17 pages, 649 KB  
Article
Implementing a Geriatric Assessment-Guided Rehabilitation Care Model in Community Oncology Care: Feasibility and Impact on Patient-Reported and Performance-Based Outcomes
by Mackenzi Pergolotti, Kelley C. Wood, Mary Hidde, Tiffany D. Kendig, Deanna Meehan, Katie Hutzayluk, Alaina M. Newell, Jessica Bertram, Ashley Lightner, Stacye Mayo, Alina Hedaya, Smith Giri and Grant R. Williams
Cancers 2025, 17(19), 3274; https://doi.org/10.3390/cancers17193274 (registering DOI) - 9 Oct 2025
Abstract
Background: Adults with cancer who are pre-frail or frail are at risk of poor outcomes. Geriatric assessment (GA) is recommended to assess and manage vulnerability and risk of frailty in older adults with cancer (≥65) and to inform referrals in supportive services, including [...] Read more.
Background: Adults with cancer who are pre-frail or frail are at risk of poor outcomes. Geriatric assessment (GA) is recommended to assess and manage vulnerability and risk of frailty in older adults with cancer (≥65) and to inform referrals in supportive services, including rehabilitation. Yet, adoption of the GA in community oncology practice lags, and frailty among adults younger than 65 often goes undetected and/or unaddressed. We evaluated the feasibility of a GA-guided rehabilitation care model and assessed changes in patient-reported and performance-based outcomes after rehabilitation. Methods: Adults (≥18 years) starting systemic therapy at a community oncology practice enrolled in the study. The GA was administered online and monthly for one year. Frailty/pre-frailty was identified using a previously validated 44-item index. The oncology team was notified of frail/pre-frail patients and then made referrals to outpatient rehabilitation. Feasibility outcomes (recruitment, retention, fidelity) and participant acceptability [7 items, 0–5 Likert scale] were analyzed descriptively. Patient-reported and performance-based outcomes were examined using the paired t-test. Results: 48% of eligible patients enrolled (N = 141), and 83% completed at least one GA. Frailty/pre-frailty was identified in 40% of the GAs, resulting in 282 referrals to rehabilitation (99% fidelity). Acceptability scores ranged from 3.5 ± 1.7 to 4.7 ± 0.6. Participants who attended rehabilitation (52%) improved significantly in outcomes measuring health-related quality of life, mobility, aerobic capacity, and strength (all p < 0.05). Conclusion: Implementing a GA-guided rehabilitation care model was feasible and acceptable to patients receiving systemic treatment. Those who attended rehabilitation experienced significant improvement in patient-reported and performance-based outcomes. Full article
(This article belongs to the Special Issue Treatment Outcomes in Older Adults with Cancer)
19 pages, 1208 KB  
Article
Local Recurrence After Nephron Surgery: What to Do? An Italian Multicentric Registry
by Angelo Porreca, Filippo Marino, Davide De Marchi, Marco Giampaoli, Daniele D’Agostino, Francesca Simonetti, Antonio Amodeo, Paolo Corsi, Francesco Claps, Alessandro Crestani, Riccardo Bertolo, Alessandro Antonelli, Fabrizio Di Maida, Andrea Minervini, Paolo Parma, Roberto Falabella, Stefano Zaramella, Francesco Greco, Maria Chiara Sighinolfi, Bernardo Rocco, Carmine Sciorio, Antonio Celia, Francesca Romana Prusciano, Pier Paolo Prontera, Gian Maria Busetto and Luca Di Gianfrancescoadd Show full author list remove Hide full author list
Cancers 2025, 17(19), 3269; https://doi.org/10.3390/cancers17193269 - 9 Oct 2025
Abstract
Introduction and Objectives: Local recurrence (LR) in patients treated with surgery for renal cell carcinoma (RCC) remains a significant clinical challenge that requires thorough investigation. Our study aimed to identify the relative risk factors and explore the optimal clinical management of LR. Materials [...] Read more.
Introduction and Objectives: Local recurrence (LR) in patients treated with surgery for renal cell carcinoma (RCC) remains a significant clinical challenge that requires thorough investigation. Our study aimed to identify the relative risk factors and explore the optimal clinical management of LR. Materials and Methods: We conducted a non-randomized, observational, retrospective multicentric registry involving multiple Italian urological centers. We included patients treated with surgery (either nephron-sparing or radical nephrectomy) who later developed LR, defined as recurrence in the ipsilateral kidney or renal fossa. Patients with hereditary syndromes or metastatic disease at the time of LR diagnosis were excluded. Results: We reported 135 cases of LR with the following characteristics: most primary lesions were monofocal (85.7%), with a median size of 42 mm (23–53), the median R.E.N.A.L. score was 7 (6–8), and the median Padua score was 7 (6–9). Patients were treated with robot-assisted techniques in 59% of cases, laparoscopic surgery in 32.4%, and open surgery in 8.6%. Nephron-sparing surgery was performed in 75.2% of cases. Ischemia occurred in 61% of the cases, with a median ischemia time of 21 min (15.5–24). Intraoperative complications occurred in 3.8% of cases, while postoperative complications were reported in 13.8%, all of which were grade ≤3 according to the Clavien–Dindo classification. The primary tumors were pT1a in 43.5% of cases, pT1b in 26.3%, pT2 in 14.7% and pT3 in 15.5%. Histologically, 84% of cases were clear cell, 11.3% papillary type 1 or 2, and 3.7% chromophobe. Sarcomatoid/rhabdoid variants were present in 10.5% of cases. The median rate of LR was 1.3% (range 0.2–3.6), while the median time to LR was 18 months (12–39). LR occurred in the ipsilateral kidney in 70.5% of cases and in the ipsilateral renal fossa in 29.5%. The median rate of PSM in LR cases at initial surgery was 2.4% (range 0–4.3), while the median rate of negative surgical margin (NSM) in LR cases at initial surgery was 0.1 (0–0.3). Following LR diagnosis, most patients (49.2%) underwent surgery, 29.1% received cryoablation or radiotherapy, 17.1% received systemic treatment alone, and 4.6% followed a watchful waiting/active surveillance approach. At a median follow-up of 62 months, the highest oncological control in terms of 5-year cancer-specific survival and overall survival rates was achieved in surgically treated patients. The PSM, the histological variant, and their combination were found to be independent variables correlated with the occurrence of LR, with relative risks of 3.62, 2.71, and 8.12, respectively. Conclusions: LR after nephron-sparing or radical nephrectomy represents a significant clinical dilemma. Known risk factors are not always sufficient to predict recurrence, emphasizing the necessity of consistent radiological follow-up per guideline recommendations. Early detection of recurrence and a multidisciplinary approach involving expert centers are crucial for optimizing patient outcomes. Full article
(This article belongs to the Special Issue Optimizing Surgical Procedures and Outcomes in Renal Cancer)
Show Figures

Figure 1

12 pages, 829 KB  
Article
Unraveling the Easix Score: Its Association with Vasopressor Need in Critically Ill Septic Pediatric Hematology–Oncology Patients
by Lama Elbahlawan, Majd Khiami, Chad Blackshear, Saad Ghafoor, Alexandra Schaller, Sherry Johnson, Gabriela Maron, Raktima Datta, Amr Qudeimat and Jennifer McArthur
J. Clin. Med. 2025, 14(19), 7105; https://doi.org/10.3390/jcm14197105 - 9 Oct 2025
Abstract
Background: Sepsis is a common and serious complication in pediatric hematology oncology (PHO) patients. The Endothelial Activation and Stress Index (EASIX) score offers a potentially accessible tool for risk stratification in septic patients. Our objective was to evaluate the association of the [...] Read more.
Background: Sepsis is a common and serious complication in pediatric hematology oncology (PHO) patients. The Endothelial Activation and Stress Index (EASIX) score offers a potentially accessible tool for risk stratification in septic patients. Our objective was to evaluate the association of the EASIX score with adverse clinical outcomes among septic PHO patients. Methods: A retrospective review was conducted for all PHO patients admitted to the intensive care unit (ICU) with sepsis from July 2022 to December 2024. Results: A total of 53 patients with 65 sepsis events were included in this analysis. The median age was 14.9 [IQR 9.9] y and the most common disease was hematologic malignancy. In our cohort, 60% needed vasopressors, 36% required invasive mechanical ventilation, and 22% underwent renal replacement therapy (RRT). Log2-EASIX > 2.5 was associated with higher vasopressor requirements (87% versus 45% in the low log2-EASIX group, p = 0.001) and an increased need for RRT (39% versus 12%, p = 0.024). Septic PHO patients with log2-EASIX > 2.5 were 6.9 times more likely to require vasopressor support [(95% CI 1.7–27.8) p = 0.007]. In addition, PHO patients with log2-EASIX > 2.5 had a longer ICU stay (7 d versus 2 d in the low log2-EASIX group, p = 0.024) and an extended overall hospitalization (33 d versus 25 d, p = 0.029). Conclusions: A higher EASIX score was associated with adverse outcomes in critically ill septic PHO patients. Our findings suggest that the EASIX score can be used as a tool for identifying septic patients at an increased risk of clinical deterioration and poor outcomes. Prospective studies in larger cohorts are warranted to validate and expand upon these findings. Full article
(This article belongs to the Special Issue Clinical Advances in Pediatric Critical Care Medicine)
Show Figures

Figure 1

32 pages, 1492 KB  
Review
Quantitative MRI in Neuroimaging: A Review of Techniques, Biomarkers, and Emerging Clinical Applications
by Gaspare Saltarelli, Giovanni Di Cerbo, Antonio Innocenzi, Claudia De Felici, Alessandra Splendiani and Ernesto Di Cesare
Brain Sci. 2025, 15(10), 1088; https://doi.org/10.3390/brainsci15101088 - 8 Oct 2025
Abstract
Quantitative magnetic resonance imaging (qMRI) denotes MRI methods that estimate physical tissue parameters in units, rather than relative signal. Typical readouts include T1/T2 relaxation (ms; or R1/R2 in s−1), proton density (%), diffusion metrics (e.g., ADC in mm2/s, FA), [...] Read more.
Quantitative magnetic resonance imaging (qMRI) denotes MRI methods that estimate physical tissue parameters in units, rather than relative signal. Typical readouts include T1/T2 relaxation (ms; or R1/R2 in s−1), proton density (%), diffusion metrics (e.g., ADC in mm2/s, FA), magnetic susceptibility (χ, ppm), perfusion (e.g., CBF in mL/100 g/min; rCBV; Ktrans), and regional brain volumes (cm3; cortical thickness). This review synthesizes brain qMRI across T1/T2 relaxometry, myelin/MT (MWF, MTR/MTsat/qMT), diffusion (DWI/DTI/DKI/IVIM), susceptibility imaging (SWI/QSM), perfusion (DSC/DCE/ASL), and volumetry using a unified framework: physics and signal model, acquisition and key parameters, outputs and units, validation/repeatability, clinical applications, limitations, and future directions. Our scope is the adult brain in neurodegenerative, neuro-inflammatory, neuro-oncologic, and cerebrovascular disease. Representative utilities include tracking demyelination and repair (T1, MWF/MTsat), grading and therapy monitoring in gliomas (rCBV, Ktrans), penumbra and tissue-at-risk assessment (DWI/DKI/ASL), iron-related pathology (QSM), and early dementia diagnosis with normative volumetry. Persistent barriers to routine adoption are protocol standardization, vendor-neutral post-processing/QA, phantom-based and multicenter repeatability, and clinically validated cut-offs. We highlight consensus efforts and AI-assisted pipelines, and outline opportunities for multiparametric integration of complementary qMRI biomarkers. As methodological convergence and clinical validation mature, qMRI is poised to complement conventional MRI as a cornerstone of precision neuroimaging. Full article
(This article belongs to the Special Issue Application of MRI in Brain Diseases)
Show Figures

Figure 1

12 pages, 1107 KB  
Article
Stenting Versus Endoscopic Vacuum Therapy for Anastomotic Leakage After Esophago-Gastric Surgery
by Carlo Galdino Riva, Stefano Siboni, Matteo Capuzzo, Francesca Senzani, Lorenzo Cusmai, Daniele Bernardi, Pamela Milito, Andrea Lovece, Eleonora Vico, Marco Sozzi and Emanuele Luigi Giuseppe Asti
J. Clin. Med. 2025, 14(19), 7075; https://doi.org/10.3390/jcm14197075 - 7 Oct 2025
Abstract
Background: Anastomotic leakage (AL) is a major complication after esophago-gastric surgery, with incidence rates of 11–21% and mortality up to 14%. Early intervention is essential to reduce morbidity. Endoscopic treatments have advanced, with self-expandable metal stents (SEMSs) as the traditional standard (success ~90%), [...] Read more.
Background: Anastomotic leakage (AL) is a major complication after esophago-gastric surgery, with incidence rates of 11–21% and mortality up to 14%. Early intervention is essential to reduce morbidity. Endoscopic treatments have advanced, with self-expandable metal stents (SEMSs) as the traditional standard (success ~90%), but they carry risks like migration, stenosis, and need for drainage. Endoscopic vacuum therapy (EVT), applying negative pressure to drain secretions and promote healing, has shown success rates of 66–100%. Limited comparative data exists from small retrospective studies. This study compares SEMS and EVT for safety and efficacy in AL management. Methods: A retrospective case–control study from a prospective database at our institution was performed (March 2012–2025). We included patients with AL post-esophageal/gastric surgery treated endoscopically (SEMS or EVT). We excluded patients treated with conservative or surgical management. Demographics, comorbidities, oncology, surgery type, leak details, treatments, and outcomes were collected. Primary outcome was complete healing of the leak, while secondary outcomes were time to success, number of procedures needed, hospital stay, complications, mortality. Results: From 592 resections, we extracted 68 AL (11.5%), 45 of which met the inclusion criteria (22 SEMS, 23 EVT). Groups were similar demographically, but SEMS had more respiratory issues (43% vs. 8.7%, p = 0.018). SEMS were used more after esophagectomy (86.4% vs. 56.5%, p = 0.004); EVT was performed mostly after gastrectomy (34.7% vs. 9.1%, p = 0.009). Success rate was 86.4% for SEMS vs. 95.6% for EVT (p = 1.000). Complications were significantly lower in EVT (8.3% vs. 50%, p = 0.001; SEMS: 36.4% migrations, 18.2% stenoses). Leak onset time, modality of diagnosis, and leak size were comparable among the groups. Need for jejunostomy was higher in EVT (43.5% vs. 9.1%, p = 0.015), while chest drains in SEMS (63.7% vs. 13.1%, p < 0.001). Hospital stays (33–38 days, p = 0.864) and mortality (22.7% vs. 8.7%, p = 0.225) were similar. No differences were observed in terms of long-term mortality (log-rank p = 0.815). Conclusions: SEMS and EVT are both effective for AL after esophago-gastric surgery. EVT offers fewer complications and shorter treatment, so it is favored especially for esophago-jejunal leaks. Full article
Show Figures

Figure 1

11 pages, 513 KB  
Systematic Review
The Safety of Negative-Pressure Wound Therapy in Melanoma and Sarcoma Patients: A Systematic Review
by Silvia Dal Pos, Stela Tafaj, Ilda Hoxhaj, Fortunato Cassalia, Francesco Russano, Saveria Tropea, Paolo Del Fiore and Marcodomenico Mazza
J. Clin. Med. 2025, 14(19), 7044; https://doi.org/10.3390/jcm14197044 - 5 Oct 2025
Viewed by 313
Abstract
Background/Objectives: Negative-Pressure Wound Therapy (NPWT) is increasingly used to promote wound healing in chronic and complicated wounds, but its use in surgical oncology is still debated due to theoretical concerns about promoting local tumor recurrence. The aim of this study is to review [...] Read more.
Background/Objectives: Negative-Pressure Wound Therapy (NPWT) is increasingly used to promote wound healing in chronic and complicated wounds, but its use in surgical oncology is still debated due to theoretical concerns about promoting local tumor recurrence. The aim of this study is to review the available evidence on the oncologic safety of NPWT, specifically regarding the risk of local recurrence in patients undergoing surgery for cutaneous melanoma (CM) or soft tissue sarcoma (STS). Methods: A systematic review of the literature was conducted using the MEDLINE/PubMed, EMBASE, and Scopus databases through December 2024 (PROSPERO: CRD42024623405). Case series, retrospective cohort studies, and randomized clinical trials reporting survival data in melanoma and sarcoma patients treated with NPWT were eligible for inclusion. PRISMA guidelines were followed and quality assessment checked. Results: Seventeen studies were eligible for the analysis with a total of 285 patients, 197 affected by soft tissue sarcoma and 88 by cutaneous melanoma. The pooled proportion of local recurrence was 5% in patients treated with NPWT, regardless of the histology considered (STS and CM). When comparing NPWT to conventional wound therapy, both the pooled risk ratio (0.87; 95% CI: 0.24–3.11; Tau2 = 0.14; I2 = 8%) and odds ratio (0.83; 95% CI: 0.20–3.39; Tau2 = 0.18) indicated no statistically significant difference in the recurrence rate. Conclusions: Current evidence does not suggest an increased risk of local recurrence associated with NPWT in melanoma or sarcoma patients, and mostly, NPWT may have important advantages over standard surgical dressings. More high-power randomized controlled trials with wider follow-up periods are needed to make it possible for practitioners to use this technique without being afraid of higher risk local recurrences. Full article
(This article belongs to the Special Issue New Advances in Wound Healing and Skin Wound Treatment)
Show Figures

Figure 1

15 pages, 799 KB  
Article
Assessment of ESGO Quality Indicators and Factors Associated with Recurrence Following Surgery for Early-Stage Cervical Cancer: A Retrospective Cohort Study
by María Espías-Alonso, Mikel Gorostidi, Ignacio Zapardiel and Myriam Gracia
J. Clin. Med. 2025, 14(19), 7041; https://doi.org/10.3390/jcm14197041 - 5 Oct 2025
Viewed by 170
Abstract
Background/Objectives: In 2019, the European Society of Gynaecological Oncology (ESGO) published a set of quality indicators (QIs) for the surgical management of cervical cancer with the aim of improving clinical practice. The objective of this study is to evaluate the influence of [...] Read more.
Background/Objectives: In 2019, the European Society of Gynaecological Oncology (ESGO) published a set of quality indicators (QIs) for the surgical management of cervical cancer with the aim of improving clinical practice. The objective of this study is to evaluate the influence of ESGO QIs and clinicopathological factors on progression-free survival (PFS) in patients with early-stage cervical cancer in a retrospective cohort. Methods: A retrospective study was conducted in patients with early-stage cervical cancer who underwent radical surgery with pelvic lymph node assessment at La Paz University Hospital between 2005 and 2022. The cohort was divided into two groups according to the timing of surgery (before vs. after 2010), when MRI was implemented as a standardized diagnostic tool and the multidisciplinary tumor board was established. Univariate and multivariate Cox regression analyses were performed, including demographic and histopathological variables, as well as adherence to ESGO QIs, focusing on those related to the overall management. Hazard ratios and 95% confidence intervals were estimated. Kaplan–Meier survival curves were generated and compared between groups. Results: The implementation of systematic MRI and a multidisciplinary tumor board at our center was associated with a significant reduction in positive surgical margins (p = 0.003) and parametrial invasion (p < 0.001), as well as improved diagnostic accuracy, lowering the rate of upstaging from 31.6% before 2010 to 4.4% thereafter (p < 0.001). PFS in the post-2010 cohort was significantly improved (log-rank p = 0.0408), although no differences in overall survival (OS) were observed (log-rank p = 0.2602). Additionally, cervical conization prior to radical hysterectomy was associated with a markedly reduced risk of recurrence (HR 0.12, p < 0.001), representing the most significant prognostic factor for PFS in our cohort. Conclusions: The correct application of ESGO QIs, along with appropriate staging and pathological assessment, is essential to improve prognosis in cervical cancer. Systematic implementation of these standards is recommended to optimize clinical care. Full article
(This article belongs to the Section Obstetrics & Gynecology)
Show Figures

Figure 1

17 pages, 1721 KB  
Article
Pleuropulmonary Blastoma in Children: A Nationwide Multicenter Study
by Barbara Tejza, Marta Hetman, Jadwiga Węcławek-Tompol, Krzysztof Kałwak, Olga Rutynowska, Bożenna Dembowska-Bagińska, Agata Sobocińska-Mirska, Paweł Łaguna, Ewa Bień, Ninela Irga-Jaworska, Katarzyna Derwich, Agnieszka Wziątek, Katarzyna Pawińska-Wąsikowska, Walentyna Balwierz, Anna Pytlik, Katarzyna Drabko, Justyna Walenciak, Wojciech Młynarski, Marta Rzeszutko and Jan Styczyński
Cancers 2025, 17(19), 3223; https://doi.org/10.3390/cancers17193223 - 2 Oct 2025
Viewed by 281
Abstract
Background/Objectives: This study involved an analysis of clinical data, histological types, genetic predisposition, treatment and outcomes in PPB in children. Patients and methods: We conducted a retrospective review of children treated for PPB at Polish pediatric oncology centers between 2011 and [...] Read more.
Background/Objectives: This study involved an analysis of clinical data, histological types, genetic predisposition, treatment and outcomes in PPB in children. Patients and methods: We conducted a retrospective review of children treated for PPB at Polish pediatric oncology centers between 2011 and 2024. Results: A total of fifteen children (seven boys, eight girls; median age of 39 months; range: 27–64 months) were included. Type II solid/cystic PPB and type III solid PPB were diagnosed in six and eight children, respectively (one not known). Overall, 93% of patients were diagnosed at up to 4 years of age. Metastatic disease at diagnosis was confirmed in three (20%) patients, localized in bones, bone marrow and lymph nodes. Diagnosis was confirmed via central pathology review in 11 patients (73%). DICER1 pathogenic variants were identified in eight patients. All children presented with respiratory symptoms. The tumor dimensions were >10 cm (n = 7), 5–10 cm (n = 5) and <5 cm (n = 2). No bilateral lung involvement was observed. Tumor biopsy was performed in six children (40%), with subsequent resection (R0) in five patients. Primary resection (R0) was achieved in three patients (20%) with type II (n = 1) or type III (n = 2). In the other six patients, non-radical resection was performed: R1 in four (27%) children (with a tumor rupture in one patient) and R2 (subtotal resection) in two children (13%). All patients received postoperative chemotherapy. Maintenance chemotherapy was given to two patients. No patient received radiotherapy as first-line treatment. Progressive disease occurred in two patients in the CNS and lungs. Relapsed disease appeared in three patients, all with CNS involvement. Conclusions: PPB is a rare, malignant tumor of early childhood with an uncertain prognosis. Despite multimodal treatment, patients remain at risk of progression or CNS relapse. Complete surgical resection remains a key prognostic factor. Full article
(This article belongs to the Section Pediatric Oncology)
Show Figures

Figure 1

17 pages, 504 KB  
Review
CIN2 in the Era of Risk-Based Management and HPV Vaccination: Epidemiology, Natural History and Guidelines
by Maria Teresa Bruno, Alessia Pagana, Carla Lo Giudice, Marco Marzio Panella, Giuseppe Mascellino and Antonio Simone Laganà
Diagnostics 2025, 15(19), 2512; https://doi.org/10.3390/diagnostics15192512 - 2 Oct 2025
Viewed by 397
Abstract
Background: Cervical intraepithelial neoplasia grade 2 (CIN2) represents a controversial lesion in cervical cancer prevention. Traditionally included in the aggregate CIN2+ endpoint for reasons of diagnostic stability and statistical power, isolated CIN2 has unique biological characteristics: greater interobserver variability, a high probability of [...] Read more.
Background: Cervical intraepithelial neoplasia grade 2 (CIN2) represents a controversial lesion in cervical cancer prevention. Traditionally included in the aggregate CIN2+ endpoint for reasons of diagnostic stability and statistical power, isolated CIN2 has unique biological characteristics: greater interobserver variability, a high probability of spontaneous regression and a lower risk of progression compared to CIN3. Objectives: To critically describe the epidemiology, natural history and management strategies of CIN2, integrating data from clinical and population-based studies and comparing the recommendations of the main international guidelines. Methods: A narrative review was conducted using a search of PubMed and Scopus (1990–January 2025). Prospective and retrospective studies on isolated CIN2, screening and vaccination trials with CIN2+ endpoints, biomarker research, and consensus documents (ASCCP, ESGO, GISCi, Ministry of Health, WHO) were included. Results: Clinical studies have shown a high probability of CIN2 regression (50–70% within two years, >70% in those <25 years), compared to a 10–15% risk of progression, especially in the presence of persistent HPV16. Screening trials and vaccine evaluations with CIN2+ endpoints have documented the efficacy of the HPV test and a dramatic reduction in lesions in vaccinated cohorts, which was also confirmed for isolated CIN2. The most recent guidelines have progressively adopted a risk-based approach, which allows for active surveillance in young women or those seeking to conceive, while the WHO maintains a screen-and-treat model in resource-limited countries. Conclusions: CIN2 is not a lesion to be treated automatically, but rather a paradigmatic model for personalized management. Integrating epidemiological and clinical data, supported by biomarkers, allows for reducing overtreatment without compromising oncological safety. Full article
(This article belongs to the Section Pathology and Molecular Diagnostics)
Show Figures

Figure 1

17 pages, 671 KB  
Systematic Review
Hydatidiform Mole with Coexisting Normal Pregnancy: A Systematic Review and Individual Participant Data Meta-Analysis
by Pier Carlo Zorzato, Alberta Ricci, Mariachiara Bosco, Liliana Galli, Laura Luka, Irene Porcari, Rosa Maria Laterza, Veronica Parolin, Michele Milella, Antonio Simone Laganà, Benjamim Ficial, Chiara Casprini, Anna Festi, Stefano Uccella and Simone Garzon
Medicina 2025, 61(10), 1781; https://doi.org/10.3390/medicina61101781 - 1 Oct 2025
Viewed by 199
Abstract
Background and Objectives: This study aimed to evaluate obstetric, neonatal, and oncologic outcomes of pregnancies complicated by a hydatidiform mole coexisting with a live fetus (HMCF) carried beyond viability, and to assess the impact of delivery mode on outcomes. Materials and Methods [...] Read more.
Background and Objectives: This study aimed to evaluate obstetric, neonatal, and oncologic outcomes of pregnancies complicated by a hydatidiform mole coexisting with a live fetus (HMCF) carried beyond viability, and to assess the impact of delivery mode on outcomes. Materials and Methods: A systematic review and individual participant data meta-analysis included HMCF cases progressing beyond 23 weeks. Obstetric and neonatal outcomes, delivery patterns, and oncologic risks were analyzed. Results: Among 118 pregnancies complicated by HMFC (124 newborns), most were complete moles (87%). Median delivery occurred at 31.6 weeks, with over half before 32 weeks. Common complications included vaginal bleeding (59%), preeclampsia (30%), and hyperthyroidism (18%). Cesarean delivery was performed in 79% of cases, often for mole-related factors, but was not associated with reduced maternal or oncologic risk. Neonatal deaths occurred exclusively in infants delivered ≤32 weeks, highlighting extreme prematurity as the key determinant of survival. Severe preeclampsia was strongly linked to earlier delivery. Conclusions: With close monitoring, continuation of HMCF pregnancies is possible. Neonatal mortality is mainly driven by prematurity, which appears to be an indirect consequence of HMFC through the development of mola-associated complications. Cesarean section does not appear to improve maternal and oncologic outcomes. Vaginal delivery can be considered when no standard contraindications exist. Full article
(This article belongs to the Section Obstetrics and Gynecology)
Show Figures

Figure 1

23 pages, 1102 KB  
Review
Therapeutic Alliances for Optimizing the Management of Patients with Prostate Cancer: SOGUG Multidisciplinary Expert Panel Recommendations
by Aránzazu González-del-Alba, Claudio Martínez Ballesteros, José Ángel Arranz, Enrique Gallardo, Regina Gironés Sarrió, Fernando López Campos, Jesús Muñoz-Rodríguez, María José Méndez-Vidal and Alfonso Gómez de Iturriaga
Cancers 2025, 17(19), 3208; https://doi.org/10.3390/cancers17193208 - 1 Oct 2025
Viewed by 362
Abstract
A group of Spanish experts of different specialties participated in the ENFOCA2 project, promoted by the Spanish Oncology Genitourinary Group (SOGUG), which was designed to provide updated information on current and novel aspects contributing to the optimal care of prostate cancer (PCa) patients. [...] Read more.
A group of Spanish experts of different specialties participated in the ENFOCA2 project, promoted by the Spanish Oncology Genitourinary Group (SOGUG), which was designed to provide updated information on current and novel aspects contributing to the optimal care of prostate cancer (PCa) patients. In localized disease, it is important to implement strategic alliances with other institutions for improving adherence to active surveillance in low-risk groups and to explore genetic testing for a better indication of focal therapy. Local control of the disease should be maximized to prevent local failure and biochemical recurrence. In patients with locally advanced disease, with PSMA PET/CT-positive lesions in M0 staging on conventional imaging techniques, therapeutic decisions should be carefully evaluated due to insufficient evidence regarding the gold standard in this setting. In patients with metastatic castration-resistant PCa (mCRPC), assessment of BRCA somatic and germline mutations provides prognostic information and familial cancer risk and informs treatment decisions. Combinations of androgen receptor signaling inhibitor (ARSi) agents and poly-ADP ribose polymerase inhibitors (PARPi) are emerging alternatives for advanced PCa. The oldest segment of PCa patients (>70 years of age) may require geriatric assessment to evaluate physical and functional reserves, tailoring treatment to their individual characteristics and circumstances. The concept of a comprehensive multidisciplinary approach together with inter-center and/or inter-specialty therapeutic alliances should be implemented in the routine care of patients with PCa. Full article
(This article belongs to the Special Issue Advances in the Management of Pelvic Tumors)
Show Figures

Figure 1

15 pages, 2584 KB  
Review
The Role of the Mediterranean Diet and Alcohol Consumption in Chronic Liver Disease Prevention: A Narrative Review
by María Barbería-Latasa, Diego Martínez-Urbistondo and Miguel A. Martínez-González
Medicina 2025, 61(10), 1777; https://doi.org/10.3390/medicina61101777 - 1 Oct 2025
Viewed by 380
Abstract
The traditional Mediterranean Diet (MedDiet) has consistently demonstrated robust benefits in reducing cardiovascular, metabolic, and oncologic risks. Its high content of anti-inflammatory and antioxidant compounds, particularly (poly)phenols, underscores why this dietary pattern has been extensively researched and widely adopted for managing various metabolic [...] Read more.
The traditional Mediterranean Diet (MedDiet) has consistently demonstrated robust benefits in reducing cardiovascular, metabolic, and oncologic risks. Its high content of anti-inflammatory and antioxidant compounds, particularly (poly)phenols, underscores why this dietary pattern has been extensively researched and widely adopted for managing various metabolic conditions. This article aims to conduct a narrative review of the association between the MedDiet (and its debated alcohol consumption pattern) and a reduced risk of liver disease, with a specific focus on the potential preventive role of the MedDiet on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which is now the most prevalent chronic liver disease globally. To carry out this review, relevant articles were searched on PubMed and other databases. The evidence found contributed to identifying the gaps in knowledge and allowed for the main findings to be summarized. Available randomized controlled trials and prospective cohort studies consistently support the hypothesis that high adherence to the MedDiet effectively reduces hepatic fat content, improves liver enzyme levels, and mitigates fibrosis progression. Crucially, this dietary pattern simultaneously addresses the significantly high cardiovascular risk inherent in MASLD. Historically, low-to-moderate alcohol intake, particularly moderate red wine with meals, was assumed to be a beneficial component of the MedDiet. While some observational studies suggest potential cardiovascular benefits, implying a loss of some MedDiet benefits if alcohol is excluded, a growing body of evidence highlights a deleterious synergistic interaction between alcohol, visceral adiposity, hepatic steatosis, and metabolic dysfunction. Based on the available evidence, clinical guidelines recommend the MedDiet with exercise for the prevention and management of MASLD. However, the alcohol consumption in the Mediterranean is currently under strong controversy. Furthermore, recent guidelines now advise total abstinence in patients with advanced liver disease and caution even at earlier MASLD stages. Yet, these assertions are largely based on observational data, underscoring the need for large clinical trials to address this issue with first-level evidence. Full article
(This article belongs to the Section Gastroenterology & Hepatology)
Show Figures

Figure 1

9 pages, 1906 KB  
Case Report
Excessive Implant Wear Reaction Mimicking Malignant Tumors: A Rare Orthopedic Case Report
by Lukas K. Kriechbaumer, Marian Mitterer, Patrick F. Marko, Sebastian Filipp, Christian Deininger, Eckhard Klieser, Andreas Hartmann and Thomas Freude
J. Clin. Med. 2025, 14(19), 6949; https://doi.org/10.3390/jcm14196949 - 1 Oct 2025
Viewed by 225
Abstract
A 75-year-old patient was transferred to the oncology department due to the discovery of a large pelvic tumor compressing the femoral neurovascular bundle suspected to be of malignant origin. Further investigation revealed a rare complication related to a 27-year-old total hip arthroplasty (THA). [...] Read more.
A 75-year-old patient was transferred to the oncology department due to the discovery of a large pelvic tumor compressing the femoral neurovascular bundle suspected to be of malignant origin. Further investigation revealed a rare complication related to a 27-year-old total hip arthroplasty (THA). The final diagnosis was a severe adverse local tissue reaction (ALTR) resulting from excessive implant wear—first from a metal-on-metal (MoM) bearing and later exacerbated by a revision to a metal-on-polyethylene (MoP) articulation. The clinical course was further complicated by periprosthetic joint infection (PJI). The patient underwent extensive tumor-like mass resection followed by two-stage revision arthroplasty. Despite these interventions, infection persisted, ultimately necessitating joint resection. This case highlights the rare but serious convergence of dreaded orthopedic complications (ALTR and PJI). It underscores the diagnostic challenge posed by wear-induced pseudotumors, which are rare even among arthroplasty specialists and are often unfamiliar to oncologists. This case illustrates the importance of early orthopedic evaluation, maintaining a high index of suspicion in atypical presentations, and invites further discussion about the interplay between ALTRs and infection risk in arthroplasty patients. Full article
Show Figures

Figure 1

13 pages, 1162 KB  
Article
Transoral Cordectomy with Microelectrodes (TOMES) on an Outpatient Basis: Advancing Patient Comfort and Personalized Care Through Predictive Models
by Cristina Rodríguez-Prado, Natsuki Oishi, Ernesto Fernández-Vidal, José Ramón Alba-García and Enrique Zapater
J. Pers. Med. 2025, 15(10), 465; https://doi.org/10.3390/jpm15100465 - 1 Oct 2025
Viewed by 151
Abstract
Background/Objectives: Outpatient surgery enhances patient comfort while reduces surgical wait times and healthcare costs compared to inpatient procedures. This study evaluates the individual feasibility of performing transoral trans muscular cordectomies with microelectrodes (TOMES) on an outpatient basis. Methods: This observational study [...] Read more.
Background/Objectives: Outpatient surgery enhances patient comfort while reduces surgical wait times and healthcare costs compared to inpatient procedures. This study evaluates the individual feasibility of performing transoral trans muscular cordectomies with microelectrodes (TOMES) on an outpatient basis. Methods: This observational study analyses TOMES types III, IV, and V cordectomies performed from January 2002 to December 2023. Key metrics include patient demographics, procedural details, incidence of bleeding, anticoagulation and other comorbidities. Results: Of the 143 procedures, 127 were cancer-related, while 16 were due to bilateral vocal cord paralysis. The average age was 65, with a predominantly male cohort (92%). Postoperative hemorrhage occurred in four cases, primarily among oncological patients, but there was no correlation with anticoagulation therapy. A personalized predictive model for bleeding risk was developed based on patient-specific characteristics and observed outcomes. Additionally, performing the procedure on an outpatient basis decreased healthcare costs and wait times for patients with T1/T2 glottic carcinoma. Conclusions: The findings indicate that TOMES type III or higher cordectomies can be safely performed on an outpatient basis, through the use of a personalized predictive model for each case and with appropriate postoperative monitoring. This approach has the potential to lower healthcare costs and improve patient quality of life through individualized assessments and structured risk analysis. Full article
(This article belongs to the Special Issue Personalized Medicine for Otolaryngology (ENT))
Show Figures

Figure 1

Back to TopTop